About FairPark II

About Fair Park II

What is FAIR PARK II? What is Parkinson’s Disease? What is iron chelation?

Who is involved in Fair Park II?


Who is involved? Who are the patients? Can I get involved?

Fair Park II Progress


Find out how we are getting on with the study through our regular updates


Recruitment for the FAIR PARK II study is now closed: The last patient has been enrolled on December 5th 2019


The FAIR-PARK II 6h annual meeting was held virtually on 22nd April 2021 

The FAIR-PARK II 5th annual meeting was held in Paris, France on 26th June 2019.

The FAIR-PARK II 4th annual meeting was held in Lisbon, Portugal on 15th and 16th June 2018.

The FAIR-PARK II 3rd annual meeting was held in Amsterdam, Netherlands on 26th and 27th June 2017.

The FAIR-PARK II 2nd annual meeting was held in Berlin, Germany on 23-24 June 2016.

The FAIR-PARK II kick-off meeting was held in Lille, France on 4-5 May 2015.

Recruitment for the FAIR PARK II study is now open: The first patient has been enrolled in Lille's hospital on February 9th 2016

The final list of European expert centres for the clinical trial is available since October 2015.

The final version of the protocol, as released by competent authorities and ethic national committees is available since january 2016


Patient Recruitment Countdown

16th December 2019

Patients to be recruited


Patients recruited


The recruitment is now closed




FAIR PARK II project: Conservative iron chelation as a therapeutic strategy to slow the progression of Parkinson’s disease

FAIR PARK II is a 5-year European project that received funding from the European Union H2020 Research and Innovation Programme in January 2015. This project will make it possible through a European clinical study to validate the efficacy and safety of an iron-trapping treatment: deferiprone. This approach by reducing cerebral iron overload, could limit neuronal death and therefore the progression of Parkinson’s disease.
This programme is coordinated by Lille University Hospital, with the support of the French NS-PARK/FCRIN networks, the European clinical research network (ECRIN), and the involvement of patients’ associations (EPDA and France Parkinson). This program brings together 15 partners, including one industrial contributor, scientists and clinicians, national leaders and coordinators of European clinical research networks dedicated to research into Parkinson’s disease.
Thanks to the involvement of these partners, 24 clinical centres with expertise in providing care for Parkinson’s disease can be associated. These 24 expert centres are spread through 8 European countries (Austria, Czech Republic, England, France, Germany, the Netherlands, Portugal and Spain) and are uniting their efforts to move research forwards, with the goal of recruiting 338 patients by 2018.

On the Iron trail:

Parkinson’s disease is caused by a progressive degeneration of neurones in a nucleus of the brain called the substantia nigra. This nucleus produces a neurotransmitter called dopamine, which plays a key role in the control of movements. Current dopamine replacing treatments make it possible to improve partially the motor symptoms (e.g.: tremor, muscular rigidity or postural instability) associated with the disease, but they do not have major effects on other non-motor symptoms (e.g.: olfactory dysfunction, cognitive impairment, autonomic dysfunction, sleep disorder, pain or fatigue) and do not halt the progression of neurone degeneration, leading to progressive worsening of patients’ disability on the long-term.
The substantia nigra contains high levels of iron concentration. The team of pharmacologists and neurologists in Lille and other groups have put forward the hypothesis that an iron trapping (sequestering or chelating) treatment might lower excessive levels of iron in order to reduce the death of neurones and limit the development of the disease. This therapeutic innovation could then be associated with the currently available symptomatic treatments.
FAIR PARK II project will make it possible to validate a new therapeutic approach via this clinical study.

FairPark I: first hope

Prof. David Devos (coordinating investigator) conducted recently a first exploratory clinical trial called FAIR PARK I. The main goal of this pilot study was to test the concept and the feasibility of treating parkinsonian patients with deferiprone, in collecting preliminary data supporting the potential efficacy of deferiprone (an iron chelating molecule) in 40 patients suffering from early-stage Parkinson’s disease.
The treatment duration was two years.
The main objectives of the FAIR PARK I study were met, as deferiprone proved to be well tolerated and patients presented encouraging signs of efficacy including some reduction in motor symptoms and slowing of disease progression after 2 years.
Based on these preliminary positive findings, further clinical studies are required to confirm the therapeutic interest of deferiprone in the treatment of Parkinson disease, and FairPark II is the first of such confirmatory trials.

FairPark II: a large-scale study

The European FAIR PARK II project represents the second pivotal step of the assessment of this new therapeutic approach and should enable verifying the results of the previous study in a broader population of patients.
This trial will include 338 patients with early-stage Parkinson’s disease. It will be a major step forwards for the development of this new therapeutic approach in contributing to improve our scientific knowledge regarding this pathology and ultimately to improve the care of the patients.
The study is sponsored by the Lille University Hospital, and supported by the French national network for clinical research in PD (NS-Park/FCRIN) and the european clinical research network (ECRIN). It is funded by the European Community under the Grant N° 633190.
The study focuses on patients between 18 and 80 years of age, suffering from Parkinson’s disease at a very early stage, at the moment of diagnosis and before any other treatment has been initiated.
These patients will be treated and followed up in one of 24 Fair Park II expert centres in Europe.

FairPark II: the goals

The main goal of this research is to assess the effect of deferiprone on the motor and non-motor symptoms that you are enduring due to Parkinson’s disease and to assess the impact of this treatment on the progressive worsening of these symptoms over time.
In other words we want to know whether deferiprone enables to improve the typical symptoms linked to Parkinson’s disease, and to reduce the progression of disability associated with such symptoms.
The hypothesis is that the score of the reference scale measuring disability in Parkinson’s disease (MDS-UPDRS) will deteriorate less on deferiprone than on placebo.
The study will also assess the tolerability and safety of deferiprone in patients suffering from early Parkinson’s disease.
Next page: How is this research going to be carried out?

How is this research going to be carried out?

This study will compare two groups of patients. One group will receive deferiprone for 9 months and the other a placebo (non-active substance). Deferiprone or placebo will be randomly awarded to patients (half and half distribution).
Deferiprone and placebo will look exactly the same (tablets administered orally twice a day: one in the morning and one in the evening). Neither the patients nor the study doctors will know which group the patients belong to, therefore they will not know which medication they are taking.
Patient’s participation in the study will last 10 months and will include 6 visits to hospital.
Clinical, biological (blood test, lumbar puncture) and radiological (MRI) examinations will be carried out during the visits to analyse more precisely the mechanisms of the disease and the interactions with the treatment. Study doctors will use several different scales to assess the symptoms relative to Parkinson’s disease in order to measure the effect of treatment. The last assessement will be made one month after the end of the treatment.


Expected benefits

From an individual viewpoint, the study treatment may moderately reduce the motor and non-motor disability linked to your disorder. It might also reduce the degree of worsening of your disease. In addition, whatever treatment you will receive, you will benefit of a personalized follow-up in a centre of expertise.
This study will also have a collective benefit because it will allow determining whether deferiprone has a significant effect on the motor complications caused by the disease and its progression; and it will eventually make it possible to improve the care provided to patients suffering from Parkinson’s disease.


What are the possible drawbacks and the foreseeable risks?

The possible drawbacks essentially concern the potential side effects of the medication used for this study.
Deferiprone (FERRIPROX®) is a treatment that is widely prescribed round the world to treat disorders associated with moderate iron excess. It is usually well tolerated and its adverse effects are well known.
The main risk, which arises in fewer than 3 % of cases, is a decrease in the white blood cell count which will not have any adverse consequences, provided that the treatment is interrupted as soon as this is observed.
Closemonitoring is planned with blood samples being taken weekly during the first 6 months (and then monthly), which will enable to stop the treatment immediately if necessary.

We’re counting on you

If you are potentially interested in taking part in this trial, please fill in the on-line questionnaire so that we can determine whether you are eligible to take part in this research or not.
This form is short and none of the data it contains will be kept. No personal information will be asked.

Form 1

Nous vous remercions d’avoir pris le temps de compléter le questionnaire. Les premières données nous indiquent que vous présentez les principaux critères pour participer à cette étude. Nous vous proposons de prendre contact avec l’équipe médicale de l’étude la plus proche de votre domicile pour obtenir des informations complémentaires et discuter de votre potentielle participation à l’étude 


Ø  Centre Expert Parkinson - Institut des Maladies Neurodégénératives, Hôpital Pellegrin, 33 000 Bordeaux

Contact : 05 57 82 14 62 / sandrine.dupouy@chu-bordeaux.fr


Ø  Hôpital Gabriel Montpied, 63000 Clermont-Ferrand

Contact : 04 73 75 49 91 / irieu@chu-clermontferrand.fr


Ø  Centre Hospitalier Regional et Universitaire de Lille , 59000 Lille

Contact : 03 20 44 59 62 /  francine.niset@chru-lille.fr


Ø  CHU de Lyon, 69677 Lyon

Contact :04 27 85 62 08 /  helene.merle@chu-lyon.fr


Ø  CHU de la Timone, 13385 Marseille

Contact :  04 91 38 43 33 manel.nouira@ap-hm.fr


Ø  Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié-Salpétrière, 75013 Paris

Contact :01  42 16 57 62,   maura.rodrigues@aphp.fr



Ø  CHU de Strasbourg, 67098 Strasbourg

Contact : +33 3 88 12 86 42/ nadia.barun@chru-strasbourg.fr


Ø  Centre d'Investigation Clinique de l'Hôpital Purpan, 31000 Toulouse

Contact : souyris.c@chu-toulouse.fr

Nous vous remercions d’avoir pris le temps de compléter le questionnaire. Les premières données nous indiquent que vous ne pouvez pas participer à cette étude. Le réseau national de recherche clinique dans la maladie de Parkinson (réseau NS-Park/ F-CRIN) mène d’autres essais cliniques, nous vous proposons de visiter les sites « NS-Park » et « Fox Trial Finder » pour avoir des informations sur les essais en cours dans le domaine. 

Form 2

Thank you for taking the time to complete this questionnaire. The initial data you have provided shows that you meet the main criteria for taking part in this study, so we suggest you to contact the closest study medical team to get additional information and discuss about your potential participation:


 University Hospital, Cambridge, UK

Contact :jacqueline.young@addenbrooks.nhs.uk


 Southern General Hospital, Glasgow, UK

Contact : +44 (0)141 201 2590/ Tracy.Murphy@ggc.scot.nhs.uk


 Newcastle University, UK

Contact : 0044 191 208 1281/ Helen.pilkington@nuth.nhs.uk

Thank you for taking the time to complete this questionnaire. This trial has very specific requirements in terms of who is suitable to take part, and unfortunately the initial data you have provided shows that we cannot include you in this study. However, there are a number of other clinical trials taking place that you may be suitable for and that might be of interest to you.


Please register with www.foxtrialfinder.com or visit www.cureparkinsons.org.uk or www.ParkinsonsMovement.com to find out about other trials that might be of interest to you.

Form 3

Danke, dass Sie sich die Zeit genommen haben, diesen Fragebogen auszufüllen. Die Angaben, die sie gemacht haben, zeigen, dass Sie die Hauptkriterien für die Teilnahme an dieser Studie erfüllen. Daher empfehlen wir, dass sie das nächste Studienzentrum kontaktieren um mehr Informationen zu erhalten und eine mögliche Teilnahme zu besprechen:


Ø  Medical University of Innsbruck, Austria.


Contact: 00 43 512 504 25810 (81553) / Katarzyna.Wachowicz@tirol-kliniken.at

Danke, dass Sie sich die Zeit genommen haben, diesen Fragebogen auszufüllen. Die Angaben, die sie gemacht haben, zeigen, dass Sie nicht an dieser Studie teilnehmen können. Es werden andere Parkinson-Studien in Ihrer Gegend durchgeführt, an denen Sie vielleicht interessiert sind. Bitte besuchen Sie dazu die Webseite des „Fox Trial Finder“ um mehr darüber zu erfahren..

Form 4

Děkujeme, že jste si udělal/a čas na vyplnění tohoto dotazníku. Počáteční údaje, které jste poskytl/a, ukazují, že jste nesplnil/a hlavní kritéria pro účast v této studii. Je možné, že probíhají další klinické studie, které jsou pro Vás vhodné. Máte-li zájem o informace ohledně výzkumu, který probíhá v této oblasti, navštivte webové stránky "Fox trial Finder", nebo se zeptejte svého neurologa. 

Děkujeme, že jste si udělal/a čas na vyplnění tohoto dotazníku. Počáteční údaje, které jste poskytl/a, ukazují, že jste splnil/a hlavní kritéria pro účast v této studii. Doporučujeme Vám, abyste se obrátil/a na nejbližší studijní lékařský tým, kde můžete získat další informace ke své potenciální účasti:


Ø  Charles University, Praha, Czech Republic

          Contact : Petra.Nesvacilova@vfn.cz

Get the latest updates via our feeds

 Get the latest updates via our feed

Subscribe to our newsletters

Subscribe to our newsletters

Contact us

 Contact us info@fairpark2.eu


Conservative iron chelation as a disease modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomised clinical trial of deferiprone

Latest News Articles

Contact Us


Scientific Coordinator: Prof David Devos
Project Manager (CHRUL): Pauline Guyon pauline.guyon@chru-lille.fr
Senior Project Manager (IT): Delphine Smagghe delphine.smagghe@inserm-transfert.fr
Project Manager (IT): Stephanie Le Naour stephanie.lenaour@inserm-transfert.fr


Centre Hospitalier Regional et Universitaire de Lille (CHRUL), 2 avenue Oscar Lambret - 59037 Lille Cedex
Inserm-Transfert (IT), 7 rue de Watt - 75013 Paris, France


Paris Inserm Transfert

Go to top